Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors
Précis: BRAFV600E-positive pediatric central nervous system tumor cells are autophagy-dependent and can be effectively targeted with combined chloroquine and vemurafenib therapy.

Obligate Progression Precedes Lung Adenocarcinoma Dissemination
Précis: Tumor-cell dissemination is a rate-limiting step in lung cancer metastasis that requires genetic alterations that can be facilitated by p53 loss and is characterized by downregulation of Nkx2-1.

SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling
Précis: Upregulation of SPSB1 enhances the survival of residual tumor cells and mediates tumor recurrence by activating c-MET signaling in aggressive breast cancer subtypes. See commentary, p. 760

Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome-Spectrum Cancers
Précis: Rare variants in RINT1 are associated with increased risk for breast cancer as well as a spectrum of cancers that are associated with DNA mismatch repair defects. See commentary, p. 762

SPSB1 May Have MET Its Match during Breast Cancer Recurrence
Y. Qin and S.S. McAllister
See article, p. 790

BluepRINT for Moderate-to-Low Penetration Cancer Susceptibility Genes Needed: Breast Cancer and Beyond
J. Ngeow and C. Eng
See article, p. 804

A Little pRB Can Lead to Big Problems
P.W. Hinds
See article, p. 840
Mulcahy Levy and colleagues report that autophagy is increased in
BRAFV600E-positive pediatric central nervous system (CNS) tumors, sug-
gesting that BRAF-mutant CNS tumors may be dependent on autophagy.
Indeed, inhibition of autophagy was cytotoxic to BRAFV600E-positive CNS
tumor cells, and the autophagy inhibitor chloroquine showed synergistic
activity with the BRAF inhibitor vemurafenib in BRAF-mutant CNS tumor
cells. The addition of chloroquine to vemurafenib overcame vemurafenib resis-
tance in primary BRAF-mutant pleomorphic xanthoastrocytoma cells, and com-
bined chloroquine and vemurafenib rapidly improved symptoms and led to durable
disease stabilization in a patient with vemurafenib-refractory BRAFV600E-positive
brainstem ganglioglioma. These findings provide a rationale for combining autophagy
inhibitors with BRAF-targeted therapy in patients with BRAF-mutant CNS tumors.
For details, please see the article by Mulcahy Levy and colleagues on page 773.